SOUTH SAN FRANCISCO, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023 at 8:00 a.m. ET.
Jefferies Healthcare Conference Information:
| Date: | Thursday, June 8, 2023 |
| Time: | 8:00 to 8:25 a.m. Eastern Time |
| Presenter: | Lawrence Blatt, Ph.D., MBA, CEO of Aligos |
| Webcast: | https://wsw.com/webcast/jeff281/algs/1840410 |
A replay of the session will be available following the conference for 90-days through the Aligos investor section of the website https://investor.aligos.com/.
The Aligos management team will also participate in investor 1x1 meetings during the conference. Please contact your Jefferies representative to schedule one-on-one meetings with Aligos during the conference.
About Aligos
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of liver diseases and viral infections. Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver and viral diseases to discover and develop potentially best in class therapeutics for nonalcoholic steatohepatitis (NASH) and viruses with high unmet medical need such as coronaviruses and chronic hepatitis B (CHB).
Media Contact
Amy Jobe, Ph.D.
LifeSci Communications
+1 315 879 8192
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$4.57 |
| Daily Change: | -0.15 -3.18 |
| Daily Volume: | 99,031 |
| Market Cap: | US$15.810M |
March 26, 2025 March 10, 2025 February 12, 2025 November 26, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
